GlassScriptPhysician profile
Sherif Michael
NPI 1699185884
$5,865.76
in general payments reported to CMS, 2019-2025
25 companies · $1,815 in 2025
The $1,815 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $408 · 2020: $152 · 2021: $35.76 · 2022: $616 · 2023: $769 · 2024: $2,070 · 2025: $1,815.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,578 · Education: $76.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,577.63 |
| Education | $76.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,950.44 | 2019-2025 | |
| Janssen Biotech, INC. | $716.66 | 2023-2025 | Tremfya, Stelara |
| Pfizer INC. | $499.83 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $414.39 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Medtronic, INC. | $264.44 | 2022-2024 | Gi Genius, Barrx, Sharkcore |
| Fujifilm Healthcare Americas Corporation | $250.00 | 2024 | Utaswako Afp-L3 |
| Evoke Pharma, INC. | $250.00 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $234.88 | 2020-2025 | Relistor, Xifaxan |
| Ardelyx, INC. | $231.71 | 2024-2025 | Ibsrela |
| Genzyme Corporation | $218.45 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $155.26 | 2024-2025 | Voquezna |
| Celgene Corporation | $125.40 | 2024 | Zeposia |
| Boston Scientific Corporation | $107.18 | 2025 | General - Hemostasis |
| Lilly USA, LLC | $68.81 | 2024-2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $61.14 | 2023-2024 | Linzess |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $60.65 | 2021-2025 | Sutab, Suflave |
| Vivus LLC | $47.94 | 2022 | |
| Intercept Pharmaceuticals, INC. | $44.82 | 2019 | |
| Ucb, INC. | $38.53 | 2020 | |
| Redhill Biopharma INC. | $29.69 | 2022 | |
| Merck Sharp & Dohme LLC | $29.10 | 2023-2024 | Dificid |
| Aimmune Therapeutics, INC. | $23.46 | 2025 | Vowst |
| Novo Nordisk INC | $15.67 | 2025 | Wegovy |
| Ferring Pharmaceuticals INC. | $15.09 | 2024 | Rebyota |
| Covidien LP | $12.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherif Michael listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.